本文選題：醫(yī)藥制造行業(yè) + 并購(gòu)績(jī)效�。� 參考：《中國(guó)財(cái)政科學(xué)研究院》2017年碩士論文

【摘要】：隨著經(jīng)濟(jì)全球化的進(jìn)程不斷加快,世界經(jīng)濟(jì)飛速發(fā)展,西方國(guó)家的六次并購(gòu)浪潮表明公司除依靠自身業(yè)務(wù)獲得發(fā)展以外,還可以通過并購(gòu)來實(shí)現(xiàn)優(yōu)化資源配置和擴(kuò)大市場(chǎng)份額。近年來,中國(guó)市場(chǎng)的并購(gòu)活動(dòng)越來越頻繁,并購(gòu)的規(guī)模和涉及的金額也越來越龐大,因此并購(gòu)活動(dòng)能否真正改善公司績(jī)效成為眾多學(xué)者關(guān)注的熱點(diǎn)問題。醫(yī)藥制造行業(yè)在我國(guó)經(jīng)濟(jì)中占有重要地位,隨著醫(yī)療體制改革、新版藥品GMP的實(shí)施,醫(yī)藥制造行業(yè)的并購(gòu)數(shù)量和并購(gòu)金額也呈現(xiàn)增長(zhǎng)趨勢(shì)。但是目前關(guān)于醫(yī)藥制造行業(yè)并購(gòu)績(jī)效的研究較少,尤其缺乏從短期和長(zhǎng)期兩個(gè)方面分析醫(yī)藥制造行業(yè)并購(gòu)績(jī)效及其影響因素的相關(guān)研究。鑒于此,本文研究的主要問題是我國(guó)醫(yī)藥制造業(yè)上市公司的并購(gòu)活動(dòng)能否改善并購(gòu)公司的績(jī)效,以及并購(gòu)績(jī)效會(huì)受到哪些因素的影響。本文首先介紹了關(guān)于并購(gòu)績(jī)效的相關(guān)理論和評(píng)價(jià)方法,對(duì)國(guó)內(nèi)外關(guān)于并購(gòu)績(jī)效的文獻(xiàn)進(jìn)行了回顧。其次分析了醫(yī)藥制造行業(yè)的并購(gòu)現(xiàn)狀、并購(gòu)特點(diǎn)、并購(gòu)動(dòng)因以及并購(gòu)績(jī)效的影響因素。再者進(jìn)行了實(shí)證研究,本文選取2007年-2012年醫(yī)藥制造業(yè)上市公司發(fā)生的并購(gòu)事件為樣本,通過建立財(cái)務(wù)指標(biāo)體系對(duì)并購(gòu)公司的短期和長(zhǎng)期績(jī)效進(jìn)行考察,并對(duì)并購(gòu)績(jī)效的影響因素進(jìn)行分析。實(shí)證研究顯示:第一,從并購(gòu)的綜合績(jī)效變動(dòng)趨勢(shì)來看,醫(yī)藥制造業(yè)上市公司并購(gòu)績(jī)效呈現(xiàn)先降后升的趨勢(shì)。并購(gòu)當(dāng)年和并購(gòu)后第一年績(jī)效有所下降,并購(gòu)后第二年績(jī)效開始回升。第二,從正值比例來看,并購(gòu)前后各年份均未有超過一半的樣本公司在并購(gòu)后經(jīng)營(yíng)業(yè)績(jī)得到提升,實(shí)施并購(gòu)的多數(shù)醫(yī)藥制造行業(yè)上市公司并未因并購(gòu)而改善業(yè)績(jī)。第三,整體而言,短期來看醫(yī)藥制造行業(yè)上市公司的并購(gòu)績(jī)效有所下降,但是從長(zhǎng)期來看,醫(yī)藥制造行業(yè)上市公司的并購(gòu)績(jī)效有上升的趨勢(shì)。第四,從并購(gòu)績(jī)效的影響因素來看,現(xiàn)金支付并購(gòu)績(jī)效低于非現(xiàn)金支付并購(gòu)績(jī)效;第一大股東為國(guó)有股的并購(gòu)績(jī)效低于非國(guó)有股并購(gòu)績(jī)效;非關(guān)聯(lián)交易的并購(gòu)績(jī)效好于關(guān)聯(lián)交易并購(gòu)。最后本文結(jié)合實(shí)證研究結(jié)果就如何提高并購(gòu)績(jī)效提出如下建議。第一,加強(qiáng)并購(gòu)后的整合力度。第二,綜合運(yùn)用多種支付手段。第三,轉(zhuǎn)變政府在并購(gòu)活動(dòng)中的角色定位,遵循市場(chǎng)規(guī)律。第四,加強(qiáng)對(duì)關(guān)聯(lián)并購(gòu)的規(guī)范。
[Abstract]:With the acceleration of the process of economic globalization and the rapid development of the world economy, six M & A waves in western countries show that companies can optimize resource allocation and expand market share through M & A in addition to their own business development. In recent years, M & A activities in Chinese market are becoming more and more frequent, and the scale and amount of M & A are becoming larger and larger. Therefore, whether M & A can really improve corporate performance has become a hot issue for many scholars. Pharmaceutical manufacturing industry plays an important role in China's economy. With the reform of medical system, the implementation of new drug GMP, the number of M & A and the amount of M & A in pharmaceutical manufacturing industry are also increasing. However, there are few researches on M & A performance of pharmaceutical manufacturing industry, especially on the analysis of M & A performance and its influencing factors in the short and long term. In view of this, the main problem of this paper is whether the M & A activities of listed companies in the pharmaceutical manufacturing industry in China can improve the performance of M & A companies, and what factors will affect the performance of M & A. This paper first introduces the relevant theories and evaluation methods of M & A performance, and reviews the literature on M & A performance at home and abroad. Secondly, it analyzes the current situation of M & A, the characteristics of M & A, the motivation of M & A and the influencing factors of M & A performance. Thirdly, this paper selects the M & A events of pharmaceutical manufacturing listed companies from 2007 to 2012 as a sample to investigate the short-term and long-term performance of M & A companies through the establishment of financial index system. And analyze the influencing factors of M & A performance. Empirical research shows that: first, from the trend of M & A comprehensive performance change, the M & A performance of pharmaceutical manufacturing listed companies shows the trend of decline first and then rising. The performance of M & A year and the first year after M & A declined, and the performance began to recover in the second year after M & A. Second, in terms of positive ratio, no more than half of the sample companies before and after M & A have improved their business performance after M & A, and most of the listed companies in the pharmaceutical manufacturing industry have not improved their performance as a result of M & A. Third, in the short run, the M & A performance of the listed companies in the pharmaceutical manufacturing industry has declined, but in the long run, the M & A performance of the listed companies in the pharmaceutical manufacturing industry has an upward trend. Fourthly, from the point of view of the influencing factors of M & A performance, the M & A performance of cash payment is lower than that of non-cash payment, the first shareholder is the state-owned stock M A performance is lower than that of non-state-owned stock M A performance. The M & A performance of non-affiliated transaction is better than that of related transaction. Finally, based on the empirical research results, this paper puts forward the following suggestions on how to improve M & A performance. First, strengthen the integration after mergers and acquisitions. Second, comprehensive use of a variety of means of payment. Third, change the role of the government in M & A activities, follow the market law. Fourth, strengthen the regulation of related mergers and acquisitions.
【學(xué)位授予單位】：中國(guó)財(cái)政科學(xué)研究院
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：F426.72;F406.7;F271

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 鄧曉嵐,王宗軍,夏天,駱杰偉;醫(yī)改背景下我國(guó)醫(yī)藥制造行業(yè)資本結(jié)構(gòu)影響因素實(shí)證分析[J];中國(guó)衛(wèi)生經(jīng)濟(jì);2005年05期

2 郭翔宇;李中華;;2006年我國(guó)各個(gè)省區(qū)醫(yī)藥制造產(chǎn)業(yè)的競(jìng)爭(zhēng)力比較分析[J];中國(guó)醫(yī)藥技術(shù)經(jīng)濟(jì)與管理;2007年03期

3 朱海旭;;醫(yī)藥制造行業(yè)2006年科技投入強(qiáng)度高[J];上海食品藥品監(jiān)管情報(bào)研究;2007年05期

4 張潔;韋曉華;;醫(yī)藥制造企業(yè)數(shù)量與行業(yè)利潤(rùn)的結(jié)構(gòu)分析[J];經(jīng)濟(jì)導(dǎo)刊;2007年S3期

5 洪涓;樊宇;;研發(fā)投入對(duì)醫(yī)藥制造產(chǎn)業(yè)影響實(shí)證分析[J];商場(chǎng)現(xiàn)代化;2008年05期

6 董秀軍;湯少梁;;外部環(huán)境對(duì)我國(guó)醫(yī)藥制造企業(yè)研發(fā)影響的文獻(xiàn)綜述[J];價(jià)值工程;2012年14期

7 徐浩鳴,徐建中,康姝麗;中國(guó)國(guó)有醫(yī)藥制造產(chǎn)業(yè)組織系統(tǒng)協(xié)同度模型及實(shí)證分析[J];中國(guó)科技論壇;2003年01期

8 鄒鮮紅;;我國(guó)大中型醫(yī)藥制造企業(yè)的技術(shù)創(chuàng)新能力研究[J];中國(guó)藥業(yè);2009年08期

9 李潔;申俊龍;;醫(yī)藥制造產(chǎn)業(yè)升級(jí)為江蘇省主導(dǎo)產(chǎn)業(yè)的可行性分析[J];江蘇商論;2010年01期

10 項(xiàng)瑩;曹陽(yáng);;我國(guó)大中型醫(yī)藥制造企業(yè)的技術(shù)創(chuàng)新能力研究[J];上海醫(yī)藥;2013年03期

相關(guān)會(huì)議論文 前2條

1 吳超;;我國(guó)醫(yī)藥制造產(chǎn)業(yè)結(jié)構(gòu)相似性研究[A];2012年中國(guó)藥學(xué)大會(huì)暨第十二屆中國(guó)藥師周論文集[C];2012年

2 薛有志;郭勇峰;姜明月;;中國(guó)醫(yī)藥制造企業(yè)前向一體化選擇及其影響的實(shí)證研究——基于企業(yè)績(jī)效和股權(quán)結(jié)構(gòu)視角[A];第五屆（2010）中國(guó)管理學(xué)年會(huì)——組織與戰(zhàn)略分會(huì)場(chǎng)論文集[C];2010年

相關(guān)重要報(bào)紙文章 前10條

1 記者 林潔;集中查處重金屬醫(yī)藥制造行業(yè)違法案件[N];汕尾日?qǐng)?bào);2014年

2 記者 吳艷榮;醫(yī)藥制造企業(yè)專項(xiàng)環(huán)境執(zhí)法檢查鎖定五重點(diǎn)[N];河北日?qǐng)?bào);2011年

3 Q孟推，

本文編號(hào)：1789846